Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Tax Provisions (2021 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Tax Provisions for 5 consecutive years, with -$71000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Tax Provisions fell 2266.67% year-over-year to -$71000.0, compared with a TTM value of -$115000.0 through Sep 2025, up 86.74%, and an annual FY2024 reading of -$44000.0, up 98.57% over the prior year.
  • Tax Provisions was -$71000.0 for Q3 2025 at Barinthus Biotherapeutics, down from -$25000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $151000.0 in Q4 2021 and bottomed at -$2.0 million in Q4 2022.
  • Average Tax Provisions over 5 years is -$400894.7, with a median of -$65000.0 recorded in 2021.
  • The sharpest move saw Tax Provisions plummeted 9528.57% in 2022, then soared 100.37% in 2024.
  • Year by year, Tax Provisions stood at $151000.0 in 2021, then plummeted by 1437.09% to -$2.0 million in 2022, then skyrocketed by 59.39% to -$820000.0 in 2023, then soared by 100.37% to $3000.0 in 2024, then tumbled by 2466.67% to -$71000.0 in 2025.
  • Business Quant data shows Tax Provisions for BRNS at -$71000.0 in Q3 2025, -$25000.0 in Q2 2025, and -$22000.0 in Q1 2025.